The Shocking Truth About Lp (a): NEW EVIDENCE

Key wellness & prevention strategies highlighted

1) Don’t rely on “standard” cholesterol panels alone

• Many lipid panels only show calculated values (and may miss important particle/metabolic signals).
• Ask about additional tests that reflect risk drivers beyond LDL.

2) Use practical “free” ratios from existing labs (insulin resistance focus)

• Triglycerides / HDL
  • < 2: decent
  • < 1: target
  • Framed as a cheap, easily available proxy for insulin resistance.
• Remnant cholesterol (calculated from standard numbers)
  • Formula: Total cholesterol − HDL − LDL
  • < 20 preferred; < 14 ideal
  • Interpreted as a metabolic/inflammatory signal: “metabolic disease wearing a cholesterol costume.”

3) Consider particle-based and advanced lipoprotein testing

• Fractionation (separates particles rather than estimating)
  • Look at LDL pattern A vs B (large/buoyant vs small/dense)
  • Pattern B = more associated with inflammation/insulin resistance.
• Lp(a) (“lipoprotein(a)”) testing
  • Suggested as a one-time (or at least once) essential test, because it’s mostly genetic and changes little with diet.
  • Threshold discussed: > 300 (ng/mL) is where treatment conversations start.

4) Treat inflammation + metabolic drivers as core risk management

• Emphasis that many mainstream doctors under-diagnose metabolic disease.
• Suggested approach includes reviewing inflammation markers (examples mentioned):
  • hs-CRP
  • myeloperoxidase
  • urine microalbumin/creatinine ratio
• Framed as: “ask for an inflammation panel” (not something the viewer must memorize).

5) Lifestyle comes first (even when considering newer drugs)

• For high Lp(a), the “default” plan is:
  • Cut glycemic carbs (specifically emphasized)
  • Exercise with intensity (within safety limits and gradual progression)
  • Manage sleep, stress, and emotional/meaning-based motivation
  • Remove barriers to healthy living
• Medication is framed as an add-on when appropriate, not the foundation:
  • Lowering biomarkers (like Lp(a)) may not automatically reduce cardiovascular events.

6) Exercise safety & programming (productivity/health habit angle)

• For interval/high-intensity training:
  • Use progressive effort, not sudden maximums.
  • A general heuristic mentioned: 220 − age for max HR, then work around ~80% zone (but safety depends on conditioning/heart status).
• Conditioning matters:
  • Someone highly trained can tolerate higher rates more safely than someone starting out.
• Key framing: don’t chase extreme exertion—build capacity gradually.

7) Fasting and supplements: minor calories don’t “break” the intent (but full protein calories negate it)

• If small amounts of calories are taken during fasting:
  • It’s described as not likely to meaningfully disrupt the main fasting effects (lower calories and dramatically lower carbs/sugar).
• Caveat:
  • If you’re taking enough protein/calories (e.g., large protein amounts), it’s no longer really a fast.

8) “Glucose Manager” supplement blend (insulin resistance support)

• A named supplement stack was described as targeting insulin resistance/metabolic health, including:
  • Berberine
  • Fenugreek seed extract (to support berberine absorption/action via gut microbiome)
  • Chromium
  • Vanadium
  • L-carnitine
  • Alpha lipoic acid

---

Main takeaways from the Lp(a) drug/news discussion

• Newer anti-sense Lp(a) therapies can lower Lp(a dramatically (e.g., ~70–90% mentioned), but the key warning was:
  • Biomarker reduction ≠ confirmed reduction in cardiovascular events (major adverse cardiovascular events).
• A proposed reason:
  • Trials may have missed metabolic disease as a co-driver, because metabolic disease is often not adequately diagnosed/treated in real-world care and research.

---

Presenters / sources

• Dr. Ford Brewer
• Dr. Jesus Vega (“Hey Zeus”)
• Novartis (named source regarding the press release/trials)
• Nardis / “Noardis” (likely the same Novartis reference as transcribed)
• No specific other studies/authors were clearly named beyond general references (e.g., “Schneiderman and others” and Valter Longo were mentioned, but not treated as formal sources with citations in the transcript).